Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)'. Together they form a unique fingerprint.

Medicine & Life Sciences